{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:07:35Z","timestamp":1770041255073,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T00:00:00Z","timestamp":1216166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00277-008-0525-5","type":"journal-article","created":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T10:55:25Z","timestamp":1216119325000},"page":"961-973","source":"Crossref","is-referenced-by-count":13,"title":["The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review"],"prefix":"10.1007","volume":"87","author":[{"given":"Nadine","family":"Shehata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam E","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Cancer Care Ontario Hematology Disease Site Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"key":"525_CR1","first-page":"29","volume":"50","author":"R Kyle","year":"1975","unstructured":"Kyle R (1975) Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50:29","journal-title":"Mayo Clin Proc"},{"key":"525_CR2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1023\/A:1008498705032","volume":"9","author":"I Moullet","year":"1998","unstructured":"Moullet I, Salles G, Ketterer N et al (1998) Frequency and significance of anemia in non-Hodgkin\u2019s lymphoma patients. Ann Oncol 9:1109\u20131115 doi: 10.1023\/A:1008498705032","journal-title":"Ann Oncol"},{"key":"525_CR3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","volume":"327","author":"LI Gordon","year":"1992","unstructured":"Gordon LI, Harrington D, Andersen J (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 327:1342","journal-title":"N Engl J Med"},{"key":"525_CR4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1995.13.9.2386","volume":"13","author":"RM Meyer","year":"1995","unstructured":"Meyer RM, Browman GP, Samosh ML et al (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 13:2386\u20132393","journal-title":"J Clin Oncol"},{"key":"525_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","volume":"28","author":"F Dammacco","year":"1998","unstructured":"Dammacco F, Silvestris F, Castoldi B (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127\u2013134 doi: 10.1007\/s005990050032","journal-title":"Int J Clin Lab Res"},{"key":"525_CR6","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A \u00d6sterborg","year":"1996","unstructured":"\u00d6sterborg A, Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin in transfusion-dependant anemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma\u2014a randomized multi-center study. Blood 87:2675\u20132682","journal-title":"Blood"},{"key":"525_CR7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Roedjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172\u2013179 doi: 10.1046\/j.1365-2141.2001.02715.x","journal-title":"Br J Haematol"},{"key":"525_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/tmrv.2003.50009","volume":"17","author":"S Kleinman","year":"2003","unstructured":"Kleinman S, Chan P, Robillard P (2003) Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 17:120\u2013162","journal-title":"Transfus Med Rev"},{"key":"525_CR9","unstructured":"The blood system for the future. In: Krever H. Commission of Inquiry on the blood system, Final Report. Ottawa, Canada. Canadian Government Publishing; 1997: 1046\u20131074. vol 3."},{"key":"525_CR10","doi-asserted-by":"crossref","unstructured":"Bohlius J, Langensiepen S, Schwarzer G, et al. (2006) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev, issue 3","DOI":"10.1002\/14651858.CD003407.pub3"},{"key":"525_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2007-08-109488","volume":"111","author":"JD Rizzo","year":"2008","unstructured":"Rizzo JD, Lichtin AE, Woolf SH et al (2008) American Society of Hematology\/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 111:25\u201341 doi: 10.1182\/blood-2007-08-109488","journal-title":"Blood"},{"key":"525_CR12","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","volume":"82","author":"FK Lin","year":"1985","unstructured":"Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82:7580\u20137584 doi: 10.1073\/pnas.82.22.7580","journal-title":"Proc Natl Acad Sci U S A"},{"key":"525_CR13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus M, Adriansson M, Miguel JS et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394\u2013403 doi: 10.1046\/j.1365-2141.2003.04448.x","journal-title":"Br J Haematol"},{"key":"525_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","volume":"119","author":"M Hedenus","year":"2002","unstructured":"Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79\u201386 doi: 10.1046\/j.1365-2141.2002.03774.x","journal-title":"Br J Haematol"},{"key":"525_CR15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","volume":"20","author":"A \u00d6sterborg","year":"2002","unstructured":"\u00d6sterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 20:2486\u20132494 doi: 10.1200\/JCO.2002.08.131","journal-title":"J Clin Oncol"},{"key":"525_CR16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rappaport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 19:2865\u20132874","journal-title":"J Clin Oncol"},{"key":"525_CR17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","volume":"155","author":"JP Garton","year":"1995","unstructured":"Garton JP, Gertz MA, Witzig TE et al (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective randomized, placebo-controlled, double blind trial. Arch Intern Med 155:2069\u20132079 doi: 10.1001\/archinte.155.19.2069","journal-title":"Arch Intern Med"},{"key":"525_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","volume":"70","author":"F Silvestris","year":"1995","unstructured":"Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313\u2013318 doi: 10.1007\/BF01696618","journal-title":"Ann Hematol"},{"key":"525_CR19","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"12","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, Mesinger D, Battister V et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood 12:4446\u20134453","journal-title":"Blood"},{"key":"525_CR20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1995.tb08374.x","volume":"89","author":"GA Pangalis","year":"1995","unstructured":"Pangalis GA, Poziopoulos C, Angelopoulou MK, Siakantaris MP, Panayiotidis P (1995) Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 89:627\u2013629 doi: 10.1111\/j.1365-2141.1995.tb08374.x","journal-title":"Br J Haematol"},{"key":"525_CR21","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1200\/JCO.2005.03.434","volume":"23","author":"M Hedenus","year":"2005","unstructured":"Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo controlled trials. J Clin Oncol 23:6941\u20136948 doi: 10.1200\/JCO.2005.03.434","journal-title":"J Clin Oncol"},{"key":"525_CR22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","volume":"12","author":"A \u00d6sterborg","year":"2005","unstructured":"\u00d6sterborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-b on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 12:206\u2013209 doi: 10.1111\/j.1365-2141.2005.05440.x","journal-title":"Br J Haematol"},{"key":"525_CR23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","volume":"122","author":"M Cazzola","year":"2003","unstructured":"Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386\u2013393 doi: 10.1046\/j.1365-2141.2003.04439.x","journal-title":"Br J Haematol"},{"key":"525_CR24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jjco\/hyl097","volume":"36","author":"Y Morishima","year":"2006","unstructured":"Morishima Y, Ogura M, Yoneda S, Sakai H, Tobinai K, Nishiwaki Y et al (2006) Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: a randomized, double-blind dose-finding study. Jpn J Clin Oncol 36:655\u2013661 doi: 10.1093\/jjco\/hyl097","journal-title":"Jpn J Clin Oncol"},{"key":"525_CR25","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","volume":"107","author":"DJ Straus","year":"2006","unstructured":"Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA (2006) Quality of life and health benefits of early treatment of mild anemia. Cancer 107:1909\u20131907 doi: 10.1002\/cncr.22221","journal-title":"Cancer"},{"key":"525_CR26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","volume":"26","author":"RE Smith","year":"2008","unstructured":"Smith RE, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE et al (2008) Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, mulitcenter randomized, double-blind, placebo controlled study. J Clin Oncol 26:1040\u20131050 doi: 10.1200\/JCO.2007.14.2885","journal-title":"J Clin Oncol"},{"key":"525_CR27","unstructured":"Straus DJ, Turner RR, Testa MA, Hayes JF, Sarokhan BJ, the Procrit Hematological Malignancies Study Group (2002) Epoetin alfa treatment improves quality of life and increase hemoglobin levels during chemotherapy for lymphoma, chronic lymphocytic leukemia and multiple myeloma patients with mild-to moderate anemia. Blood 100(11) Abstract 828"},{"key":"525_CR28","unstructured":"Rose E, Rai K, Revicki D, Brown R, Reblando J (1994) Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 526a. Abstract 2091."},{"issue":"Suppl 5","key":"525_CR29","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/0959-8049(95)95490-W","volume":"31A","author":"K Rai","year":"1995","unstructured":"Rai K, Rose E, Revicki D, Brown R, Reblando J (1995) Clinical and health status assessments in anaemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa. Eur J Cancer 31A(Suppl 5):S50\u20131 A232 (abstract)","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"525_CR30","first-page":"S202","volume":"4","author":"A Rubio-Martinez","year":"2003","unstructured":"Rubio-Martinez A, Recasens V, Mayayo P, Montanes A, Rubio-F\u00e9lix D, Giraldo P (2003) Anaemia associated to multiple myeloma: response to epoetin alpha. Hematol J 4(Suppl 1):S202 A258 (abstract)","journal-title":"Hematol J"},{"key":"525_CR31","doi-asserted-by":"crossref","unstructured":"Delarue R, Mounier N, Haioun C, Coiffier R, Gisselbrecht C, Ghesquieres H, et al. (2006) Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B Randomized GELA Study. Blood 108. Abstract 2436","DOI":"10.1182\/blood.V108.11.2436.2436"},{"key":"525_CR32","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMp078101","volume":"356","author":"FR Khuri","year":"2007","unstructured":"Khuri FR (2007) Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356:2445 doi: 10.1056\/NEJMp078101","journal-title":"N Engl J Med"},{"key":"525_CR33","unstructured":"Food and Drug Administration Oncologic Drugs Advisory Committee May 4, 2004 Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/4037b2.htm.Accessed May 2008"},{"issue":"8","key":"525_CR34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","volume":"4","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B, BEST Investigators and Study Group (2003) . Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8):459\u2013460 doi: 10.1016\/S1470-2045(03)01163-X","journal-title":"Lancet Oncol"},{"key":"525_CR35","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","volume":"25","author":"JR Wright","year":"2007","unstructured":"Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027\u20131032 doi: 10.1200\/JCO.2006.07.1514","journal-title":"J Clin Oncol"},{"key":"525_CR36","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszing R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patient with anaemia undergoing radiotherapy: randomized, double-blind, placebo controlled trial. Lancet 362:1255\u20131260 doi: 10.1016\/S0140-6736(03)14567-9","journal-title":"Lancet"},{"key":"525_CR37","unstructured":"Communication about an Ongoing Safety Review: Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) http:\/\/www.fda.gov\/cder\/drug\/early_comm\/ESA.htm . Accessed April 2, 2008."},{"key":"525_CR38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","volume":"299","author":"CL Bennett","year":"2008","unstructured":"Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914\u2013924 doi: 10.1001\/jama.299.8.914","journal-title":"JAMA"},{"key":"525_CR39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00451726","volume":"3","author":"P Hopwood","year":"1994","unstructured":"Hopwood P, Stephens RJ, Machin D (1994) Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. MRC Lung Cancer Working Party Qual Life Res 3:339\u2013352 doi: 10.1007\/BF00451726","journal-title":"Qual Life Res"},{"key":"525_CR40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00540022","volume":"5","author":"M Staquet","year":"1996","unstructured":"Staquet M, Berzon R, Osoba D, Machin D (1996) Guidelines for reporting results of quality of life assessment in clinical trials. Qual Life Res 5:496\u2013502 doi: 10.1007\/BF00540022","journal-title":"Qual Life Res"},{"key":"525_CR41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979\u2013986 doi: 10.1093\/annonc\/mdh235","journal-title":"Ann Oncol"},{"key":"525_CR42","first-page":"68","volume":"47","author":"DL Streiner","year":"2002","unstructured":"Streiner DL (2002) The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychol 47:68\u201375","journal-title":"Can J Psychol"},{"key":"525_CR43","unstructured":"National Institute for Health and Clinical Excellence Appraisal consultation document\u2014erythropoietin for anaemia induced by cancer treatment. Online resource. Available at: http:\/\/www.nice.org.uk\/page.aspx?o=263492 . Accessed: November, 2007."},{"key":"525_CR44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","volume":"43","author":"C Bokemeyer","year":"2007","unstructured":"Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. 2006 update. Eur J Cancer 43:258\u2013270 doi: 10.1016\/j.ejca.2006.10.014","journal-title":"Eur J Cancer"},{"key":"525_CR45","unstructured":"National Comprehensive Cancer Network Clinical practice guidelines in oncology. Cancer- and treatment-related anemia. Version 2.2005. Online resource. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/anemia.pdf . Accessed: March 2, 2006"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0525-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0525-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0525-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T01:08:00Z","timestamp":1588813680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0525-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0525-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,16]]}}}